Kleiner Perkins Caufield & Byers are committed to helping entrepreneurs build enduring market-changing institutions, defining new business sectors or expanding existing ones. Since 1972, their partners have supported hundreds of entrepreneurs in building over 475 companies, including such household names as Amazon, Sun, Genentech, Intuit, Verisign and Google.

They work tirelessly on behalf of entrepreneurs and share the benefits of their experience to develop new enterprises. Their Relationship Capital creates an informal, far-reaching network to assist entrepreneurs as they learn from one another and build the great businesses of tomorrow.

KPCB is constantly on the lookout for ideas with the promise to invent new business categories or radically alter existing ones. Their passion is for new technologies and new applications of technology that will drive high-impact change.
www.kpcb.com

De Novo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would have significant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by our investment success in selected medical device and biotechnology companies.  

With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. We invest in all stages of enterprise development and growth – from early stage to late stage. Our unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.
www.denovovc.com

New Leaf Venture Partners is a leader in healthcare technology venture investing. Their investment professionals bring a unique blend of technological, clinical, and operational experience to their investments. New Leaf works closely with their entrepreneurs to help build successful portfolio companies. They focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

New Leaf currently manages $1.3 billion in assets. This includes their newest fund, New Leaf Ventures II, L.P. which closed with commitments of $450 million in October 2007, New Leaf Ventures I, L.P. and the healthcare technology portfolio of the Sprout Group, one of the oldest U.S. venture capital fund groups.
www.nlvpartners.com